Risk Outlining and Uncertainty Contour for Quantification of Acyclovir Using LC-MS: Solicitation to in Vitro Cell Line Studies

Outlining of risk profile and uncertainty estimation are the two chief and significant strictures that need to be adopted during the development of pharmaceutical process, to ensure reliable results. In this era, the conventional method validation agenda needs to be extemporized so as to certify extraordinary method reliability to measure quality attribute of a drug product. In this research work, risk sketch and expanded uncertainty in the analysis of acyclovir were studied. LC-MS method was validated in our laboratory as per ICH guidelines and risk profile has been outlined including uncertainty estimation using the cause-effect approach. In the course of validation, the calibration model found to be defensible when encountered with Levene’s and lack of fit test. The proposed research work evidently demonstrates the application of theoretical concepts of uncertainty and risk profile in the methods used for analysis in drug discovery process.

[1]  D. Leung,et al.  Development and validation of a plasma assay for acyclovir using high-performance capillary electrophoresis with sample stacking. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  H. Pitkow,et al.  Basic and Clinical Pharmacology , 1983 .

[3]  H. C. Prameela,et al.  Simple spectrophotometric determination of acyclovir in bulk drug and formulations. , 2002, Farmaco.

[4]  U. Brinkman,et al.  High-performance liquid chromatographic determination of amantadine in urine after micelle-mediated pre-column derivatization with 1-fluoro-2,4-dinitrobenzene. , 1990, Journal of pharmaceutical and biomedical analysis.

[5]  S. Todo,et al.  Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  Vicki J. Barwick,et al.  Measurement uncertainty: Approaches to the evaluation of uncertainties associated with recovery† , 1999 .

[7]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: isoniazid. , 2007, Journal of pharmaceutical sciences.

[8]  M. Macka,et al.  Determination of Acyclovir in Blood Serum and Plasma by Micellar Liquid Chromatography with Fluorimetric Detection , 1993 .

[9]  H. C. Prameela,et al.  Simple high-performance liquid chromatographic method for the determination of acyclovir in pharmaceuticals. , 2003, Farmaco.

[10]  Y. Itoh,et al.  A simple and simultaneous determination of acyclovir and ganciclovir in human plasma by high-performance liquid chromatography. , 2003, Biomedical chromatography : BMC.

[11]  Jack A. Cook,et al.  Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond , 2008, The AAPS Journal.

[12]  H. Aboul‐Enein,et al.  Estimation of Uncertainty for Measuring Codeine Phosphate Tablets Formulation Using UV-Vis Spectrophotometry , 2010 .

[13]  M Laurentie,et al.  Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal--part II. , 2004, Journal of pharmaceutical and biomedical analysis.

[14]  G. Elion,et al.  In vitro susceptibility of varicella-zoster virus to acyclovir , 1980, Antimicrobial Agents and Chemotherapy.

[15]  H. Leis,et al.  Quantitative analysis of memantine in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry. , 2002, Journal of mass spectrometry : JMS.

[16]  C. Vora,et al.  A newfangled study using risk silhouette and uncertainty approximation for quantification of acyclovir in diverse formulation , 2014, Journal of pharmaceutical analysis.

[17]  H. Daabees The Use of Derivative Spectrophotometry for the Determination of Acyclovir and Diloxanide Furoate in Presence of Impurity or Degradation Product , 1998 .

[18]  H. Hundt,et al.  Automated high-performance liquid chromatographic method for the determination of acyclovir in plasma. , 1994, Journal of chromatography. A.

[19]  M Laurentie,et al.  Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal--part III. , 2007, Journal of pharmaceutical and biomedical analysis.

[20]  Stacy D. Brown,et al.  Determination of acyclovir in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[21]  R. Boulieu,et al.  Determination of acyclovir in human plasma by high-performance liquid chromatography. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[22]  S. Tadepalli,et al.  Scintillation proximity radioimmunoassay for the measurement of acyclovir. , 1996, Journal of pharmaceutical and biomedical analysis.

[23]  S. Skoulika,et al.  Rapid, Noninvasive Quantitative Determination of Acyclovir in Pharmaceutical Solid Dosage Forms through Their Poly(Vinyl Chloride) Blister Package by Solid-State Fourier Transform Raman Spectroscopy , 2003, Applied spectroscopy.

[24]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: aciclovir. , 2008, Journal of pharmaceutical sciences.

[25]  M. Sultan Spectrophotometric determination of acyclovir in some pharmaceutical formulations. , 2002, Farmaco.

[26]  B. Katzung Basic and Clinical Pharmacology , 1982 .